NEW_CURA-LEAF_1170x120_OCT

Novo Nordisk

Abbott and Novo Nordisk to provide integrated digital solution to people with diabetes using insulin

Abbott and Novo Nordisk  to provide integrated digital solution to people with diabetes using insulin

ABBOTT PARK, Ill. —Abbott and Novo Nordisk announced Wednesday a non-exclusive partnership that will integrate insulin dose data from Novo Nordisk pre-filled and durable connected pens directly into the digital health tools compatible with the FreeStyle Libre system (FreeStyle LibreLinkii mobile app and LibreViewiii cloud-based system). The partnership reflects both companies′ commitment to make diabetes

Hy-Vee to provide free A1C screenings in November

Hy-Vee to provide free A1C screenings in November

WEST DES MOINES, Iowa — In honor of National Diabetes Awareness Month, Hy-Vee, Inc. will provide free Hemoglobin A1C screenings throughout its eight-state region during the month of November. The free Hemoglobin A1C screenings will be offered on a first-come, first-served basis at the Hy-Vee Healthy You Mobiles in 168 Hy-Vee store parking lots. Hy-Vee

Novo Nordisk launches Ozempic, Fiasp in U.S.

Novo Nordisk launches Ozempic, Fiasp in U.S.

PLAINSBORO, N.J. — Novo Nordisk has released two new diabetes medications, Ozempic (semaglutide injection 0.5 mg and 1 mg) and Fiasp (insulin aspart injection 100 units/ml), to U.S. pharmacies. Both medications gained Food and Drug Administration approval in 2017 and mark the latest advancements to Novo Nordisk’s diabetes portfolio, the company said Monday. Ozempic is a

Novo Nordisk set to release Ozempic

Novo Nordisk set to release Ozempic

PLAINSBORO, N.J. — Novo Nordisk this week gained Food and Drug Administration approval for Ozempic (semaglutide injection), a medication for type 2 diabetes. Also this week, Novo Nordisk and pharmacy benefit manager Prime Therapeutics said they signed a value-based contract for Victoza (liraglutide injection), another type 2 diabetes medication. A glucagon-like peptide (GLP-1) receptor agonist,

Novo Nordisk releases Xultophy 100/3.6 insulin pen

Novo Nordisk releases Xultophy 100/3.6 insulin pen

PLAINSBORO, N.J. — Novo Nordisk has launched Xultophy 100/3.6, a combination therapy insulin pen, at pharmacies nationwide. Xultophy 100/3.6 combines the long-acting basal insulin Tresiba (insulin degludec U-100) with the No. 1-prescribed glucagon-like peptide-1 receptor agonist (GLP1-RA) therapy Victoza (liraglutide 3.6 mg/ml) in a once-daily injection, Novo Nordisk said. The prefilled pen is indicated as

CVS launches PBM Rx savings program

WOONSOCKET, R.I. — CVS Health last month announced the launch of Reduced Rx, a prescription savings program offering discounts on certain medications directly to patients through the company’s pharmacy benefits manager, CVS Caremark. The announcement came a day after the company reported that prescription growth for CVS Caremark clients slowed in 2016 to its lowest

CVS to launch Reduced Rx savings program

CVS to launch Reduced Rx savings program

WOONSOCKET, R.I. — CVS Health plans to serve up discounts on certain medications via a new prescription drug savings program called Reduced Rx. CVS said Thursday that Reduced Rx is designed to help patients with high out-of-pocket costs afford vital medications. The discounts will be offered directly to patients through CVS Caremark, the company’s pharmacy benefit

Novo Nordisk announces CEO succession

Novo Nordisk announces CEO succession

BAGSVÆRD, Denmark — Lars Rebien Sørensen, president and chief executive officer of Novo Nordisk A/S, is retiring from the company and will be succeeded by Lars Fruergaard Jørgensen. Plans call for Jørgensen, executive vice president and head of corporate development, to take the CEO reins on Jan. 1, Novo Nordisk said Thursday. Sørensen is slated to

Novo Nordisk breaks ground on diabetes medicine facility

Novo Nordisk breaks ground on diabetes medicine facility

CLAYTON, N.C. — Novo Nordisk Inc. has broken ground on a new $1.8 billion diabetes medicine production facility in Clayton, N.C. The 833,000-square-f00t Clayton facility will make active pharmaceutical ingredients (API) for a range of Novo Nordisk’s current and future GLP-1 and insulin medicines. Plans call for the facility to become fully operational in 2020

Novo Nordisk releases Tresiba long-acting insulin

Novo Nordisk releases Tresiba long-acting insulin

PLAINSBORO, N.J. — Novo Nordisk Inc. has rolled out Tresiba, a once-daily, long-acting basal insulin, to U.S. pharmacies. Novo Nordisk said Tuesday that Tresiba (insulin degludec injection), provides a more flexible option for adults with diabetes who require insulin therapy, who often must plan their schedules to accommodate the need to take insulin at the

Novo Nordisk buys pair of biopharma companies

Novo Nordisk buys pair of biopharma companies

BAGSVAERD, Denmark — Novo Nordisk plans to acquire Calibrium LLC and MB2 LLC, two privately held biopharmaceutical research companies based in Carmel, Ind. The Danish pharmaceutical company said Thursday that the acquisition will expand its portfolio of projects and intellectual property rights in the diabetes and obesity segments and help expand Novo Nordisk’s research presence

Walgreens program promotes healthier behaviors

Walgreens program promotes healthier behaviors

DEERFIELD, Ill. — A new white paper from Walgreens finds that its Balance Rewards for healthy choices (BRhc) loyalty program is encouraging healthier behaviors by members, including weight loss and improved medication adherence by those with hypertension and/or diabetes. The drug chain said Thursday that the white paper data, from a series of related Walgreens

Novo Nordisk releases Saxenda weight-control pen in U.S.

Novo Nordisk releases Saxenda weight-control pen in U.S.

PLAINSBORO, N.J. — Novo Nordisk Inc. has launched Saxenda, a weight-control drug delivered via an injector pen, in the United States. The company said Wednesday that Saxenda (liraglutide injection) is the first, once-daily glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management in adults. Saxenda is indicated as an adjunct to a reduced-calorie diet and